Log in

Relevant bibliographies by topics / Pharmaceutical delivery technologies / Journal articles

Journal articles on the topic 'Pharmaceutical delivery technologies'

To see the other types of publications on this topic, follow the link: Pharmaceutical delivery technologies.

Author: Grafiati

Published: 10 December 2022

Last updated: 28 January 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Pharmaceutical delivery technologies.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Marcato, Priscyla D., and Nelson Durán. "New Aspects of Nanopharmaceutical Delivery Systems." Journal of Nanoscience and Nanotechnology 8, no. 5 (May 1, 2008): 2216–29. http://dx.doi.org/10.1166/jnn.2008.274.

Full text

Abstract:

Nanobiotechnology, involving biological systems manufactured at the molecular level, is a multidisciplinary field that has fostered the development of nanoscaled pharmaceutical delivery devices. Micelles, liposomes, solid lipid nanoparticles, polymeric nanoparticles, functionalized nanoparticles, nanocrystals, cyclodextrins, dendrimers, nanotubes and metallic nanoparticles have been used as strategies to deliver conventional pharmaceuticals or substances such as peptides, recombinant proteins, vaccines and nucleotides. Nanoparticles and other colloidal pharmaceutical delivery systems modify many physicochemical properties, thus resulting in changes in the body distribution and other pharmacological processes. These changes can lead to pharmaceutical delivery at specific sites and reduce side effects. Therefore, nanoparticles can improve the therapeutic efficiency, being excellent carriers for biological molecules, including enzymes, recombinant proteins and nucleic acid. This review discusses different pharmaceutical carrier systems, and their potential and limitations in the field of pharmaceutical technology. Products with these technologies which have been approved by the FDA in different clinical phases and which are on the market will be also discussed.

APA, Harvard, Vancouver, ISO, and other styles

2

Sullivan, Vincent J., John A. Mikszta, Philippe Laurent, Juan Huang, and Brandi Ford. "Noninvasive delivery technologies: respiratory delivery of vaccines." Expert Opinion on Drug Delivery 3, no. 1 (December 22, 2005): 87–95. http://dx.doi.org/10.1517/17425247.3.1.87.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Rossi, Alessandra. "Innovative Technologies for Oral Drug Delivery." Current Drug Delivery 10, no. 1 (February 1, 2013): 4–8. http://dx.doi.org/10.2174/1567201811310010003.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Jain, Deepika, Vikas Jain, and Ranjit Singh. "Novel antigen delivery technologies: a review." Drug Delivery and Translational Research 1, no. 2 (January 25, 2011): 103–12. http://dx.doi.org/10.1007/s13346-011-0014-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Phillips, Brett E., and Nick Giannoukakis. "Drug delivery technologies for autoimmune disease." Expert Opinion on Drug Delivery 7, no. 11 (October 20, 2010): 1279–89. http://dx.doi.org/10.1517/17425247.2010.527329.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Sant, Shilpa, Sarah L. Tao, Omar Z. Fisher, Qiaobing Xu, Nicholas A. Peppas, and Ali Khademhosseini. "Microfabrication technologies for oral drug delivery." Advanced Drug Delivery Reviews 64, no. 6 (May 2012): 496–507. http://dx.doi.org/10.1016/j.addr.2011.11.013.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Benson, Heather A. E., Jeffrey E. Grice, Yousuf Mohammed, Sarika Namjoshi, and Michael S. Roberts. "Topical and Transdermal Drug Delivery: From Simple Potions to Smart Technologies." Current Drug Delivery 16, no. 5 (May 29, 2019): 444–60. http://dx.doi.org/10.2174/1567201816666190201143457.

Full text

Abstract:

This overview on skin delivery considers the evolution of the principles of percutaneous absorption and skin products from ancient times to today. Over the ages, it has been recognised that products may be applied to the skin for either local or systemic effects. As our understanding of the anatomy and physiology of the skin has improved, this has facilitated the development of technologies to effectively and quantitatively deliver solutes across this barrier to specific target sites in the skin and beyond. We focus on these technologies and their role in skin delivery today and in the future.

APA, Harvard, Vancouver, ISO, and other styles

8

Simerska, Pavla, Peter Moyle, Colleen Olive, and Istvan Toth. "Oral Vaccine Delivery – New Strategies and Technologies." Current Drug Delivery 6, no. 4 (August 1, 2009): 347–58. http://dx.doi.org/10.2174/156720109789000537.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Obata, Yoko, Tomoya Nishino, and Shigeru Kohno. "Technologies of Drug Delivery System for Nephrology." Drug Delivery System 27, no. 4 (2012): 257–66. http://dx.doi.org/10.2745/dds.27.257.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Mohammed, Abdullah, Amr Elshaer, Pooya Sareh, Mahmoud Elsayed, and Hany Hassanin. "Additive Manufacturing Technologies for Drug Delivery Applications." International Journal of Pharmaceutics 580 (April 2020): 119245. http://dx.doi.org/10.1016/j.ijpharm.2020.119245.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Mustata, Gabriela, and Steven M. Dinh. "Drug delivery global summit – evaluating emerging technologies." Expert Opinion on Drug Delivery 2, no. 1 (January 2005): 185–87. http://dx.doi.org/10.1517/17425247.2.1.185.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Palanki, Rohan, William H. Peranteau, and Michael J. Mitchell. "Delivery technologies for in utero gene therapy." Advanced Drug Delivery Reviews 169 (February 2021): 51–62. http://dx.doi.org/10.1016/j.addr.2020.11.002.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Reddy, Deshika, Viness Pillay, Yahya E. Choonara, and Lisa C. du Toit. "Rapidly disintegrating oramucosal drug delivery technologies." Pharmaceutical Development and Technology 14, no. 6 (November 3, 2009): 588–601. http://dx.doi.org/10.3109/10837450902838700.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

Khan, Zaheeda, Viness Pillay, Yahya E. Choonara, and Lisa C. du Toit. "Drug delivery technologies for chronotherapeutic applications." Pharmaceutical Development and Technology 14, no. 6 (November 3, 2009): 602–12. http://dx.doi.org/10.3109/10837450902922736.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Khan, Zaheeda, Viness Pillay, Yahya E. Choonara, and Lisa C. du Toit. "Drug delivery technologies for chronotherapeutic applications." Pharmaceutical Development and Technology 00, no. 00 (May 5, 2009): 090505061814070–12. http://dx.doi.org/10.1080/10837450902922736.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Wahlich, John, Arpan Desai, Francesca Greco, Kathryn Hill, Arwyn T. Jones, Randall J. Mrsny, Gianfranco Pasut, et al. "Nanomedicines for the Delivery of Biologics." Pharmaceutics 11, no. 5 (May 3, 2019): 210. http://dx.doi.org/10.3390/pharmaceutics11050210.

Full text

Abstract:

A special symposium of the Academy of Pharmaceutical Sciences Nanomedicines Focus Group reviewed the current status of the use of nanomedicines for the delivery of biologics drugs. This meeting was particularly timely with the recent approval of the first siRNA-containing product Onpattro™ (patisiran), which is formulated as a lipid nanoparticle for intravenous infusion, and the increasing interest in the use of nanomedicines for the oral delivery of biologics. The challenges in delivering such molecules were discussed with specific emphasis on the delivery both across and into cells. The latest developments in Molecular Envelope Technology® (Nanomerics Ltd, London, UK), liposomal drug delivery (both from an academic and industrial perspective), opportunities offered by the endocytic pathway, delivery using genetically engineered viral vectors (PsiOxus Technologies Ltd, Abingdon, UK), Transint™ technology (Applied Molecular Transport Inc., South San Francisco, CA, USA), which has the potential to deliver a wide range of macromolecules, and AstraZeneca’s initiatives in mRNA delivery were covered with a focus on their uses in difficult to treat diseases, including cancers. Preclinical data were presented for each of the technologies and where sufficiently advanced, plans for clinical studies as well as early clinical data. The meeting covered the work in progress in this exciting area and highlighted some key technologies to look out for in the future.

APA, Harvard, Vancouver, ISO, and other styles

17

Mufamadi, Maluta S., Viness Pillay, Yahya E. Choonara, Lisa C. Du Toit, Girish Modi, Dinesh Naidoo, and Valence M. K. Ndesendo. "A Review on Composite Liposomal Technologies for Specialized Drug Delivery." Journal of Drug Delivery 2011 (February 8, 2011): 1–19. http://dx.doi.org/10.1155/2011/939851.

Full text

Abstract:

The combination of liposomes with polymeric scaffolds could revolutionize the current state of drug delivery technology. Although liposomes have been extensively studied as a promising drug delivery model for bioactive compounds, there still remain major drawbacks for widespread pharmaceutical application. Two approaches for overcoming the factors related to the suboptimal efficacy of liposomes in drug delivery have been suggested. The first entails modifying the liposome surface with functional moieties, while the second involves integration of pre-encapsulated drug-loaded liposomes within depot polymeric scaffolds. This attempts to provide ingenious solutions to the limitations of conventional liposomes such as short plasma half-lives, toxicity, stability, and poor control of drug release over prolonged periods. This review delineates the key advances in composite technologies that merge the concepts of depot polymeric scaffolds with liposome technology to overcome the limitations of conventional liposomes for pharmaceutical applications.

APA, Harvard, Vancouver, ISO, and other styles

18

Firooz, Alireza, Roshanak Namdar, Shohreh Nafisi, and Howard I. Maibach. "Nano-Sized Technologies for Miconazole Skin Delivery." Current Pharmaceutical Biotechnology 17, no. 6 (April 11, 2016): 524–31. http://dx.doi.org/10.2174/1389201017666160301102459.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Collins, Bob. "A trick of the light: Novel technologies for sizing liposomal drug-delivery particles." Biochemist 28, no. 2 (April 1, 2006): 25–27. http://dx.doi.org/10.1042/bio02802025.

Full text

Abstract:

Since their inception in the mid-1960s, liposomes have become an important, if not the critical, nanoparticle in the pharmaceutical industry, with applications ranging from magnetic resonance imaging to biosensors to drug delivery1. In the area of drug delivery there are presently over 30 liposome formulations involved in clinical trials at the U.S. Food and Drug Administration, targeting breast, prostate and ovarian cancer, among others.

APA, Harvard, Vancouver, ISO, and other styles

20

Awad, Atheer, Christine M. Madla, Laura E. McCoubrey, Fabiana Ferraro, Francesca K. H. Gavins, Asma Buanz, Simon Gaisford, et al. "Clinical translation of advanced colonic drug delivery technologies." Advanced Drug Delivery Reviews 181 (February 2022): 114076. http://dx.doi.org/10.1016/j.addr.2021.114076.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Rabiei, Morteza, Soheila Kashanian, Seyedeh Sabereh Samavati, Shahriar Jamasb, and Steven J. P. McInnes. "Nanomaterial and advanced technologies in transdermal drug delivery." Journal of Drug Targeting 28, no. 4 (December 18, 2019): 356–67. http://dx.doi.org/10.1080/1061186x.2019.1693579.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Kolakovic, Ruzica, Tapani Viitala, Petri Ihalainen, Natalja Genina, Jouko Peltonen, and Niklas Sandler. "Printing technologies in fabrication of drug delivery systems." Expert Opinion on Drug Delivery 10, no. 12 (November 21, 2013): 1711–23. http://dx.doi.org/10.1517/17425247.2013.859134.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Filgueira, Carly S., Stephen R. Igo, Dennis K. Wang, Matteo Hirsch, Daryl G. Schulz, Brian A. Bruckner, and Alessandro Grattoni. "Technologies for intrapericardial delivery of therapeutics and cells." Advanced Drug Delivery Reviews 151-152 (November 2019): 222–32. http://dx.doi.org/10.1016/j.addr.2019.02.006.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Ahadian, Samad, Joel A. Finbloom, Mohammad Mofidfar, Sibel Emir Diltemiz, Fatemeh Nasrollahi, Elham Davoodi, Vahid Hosseini, et al. "Micro and nanoscale technologies in oral drug delivery." Advanced Drug Delivery Reviews 157 (2020): 37–62. http://dx.doi.org/10.1016/j.addr.2020.07.012.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Manikkath, Jyothsna, and J. Anand Subramony. "Toward closed-loop drug delivery: Integrating wearable technologies with transdermal drug delivery systems." Advanced Drug Delivery Reviews 179 (December 2021): 113997. http://dx.doi.org/10.1016/j.addr.2021.113997.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Musthafa, Jezila, and Bodipudi Sravani. "Utilization of Drug Delivery Technologies & Screening in Present Day Drug Development and Discovery." Journal of Pharmaceutical Research and Innovation 1, no. 1 (July 9, 2021): 1–7. http://dx.doi.org/10.36647/jpri/01.01.a001.

Full text

Abstract:

In this following thesis the technologies that offer an effectiveness and efficiency during drug delivery will be discussed in an explained and detailed way. Drug delivery can be considered towards the engagement in order to manufacture systems, formulation, storage systems or inventory and other critical technologies that can offer sufficient work efficiency and smoothness in the area of transporting towards the destined site. This essential movement provides desired therapeutic effects in requirement of drug development and delivering a pharmaceutical compound towards the target area. Keyword : — Drug, Drug development, Technologies, Pharmaceutical, transportation

APA, Harvard, Vancouver, ISO, and other styles

27

Ichikawa, Hideki. "[FOREWORD] Recent progress in pharmaceutical technologies for particulate drug delivery systems." Drug Delivery System 30, no. 2 (2015): 89. http://dx.doi.org/10.2745/dds.30.89.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Shantha Kumar, T., K. Soppimath, and S. Nachaegari. "Novel Delivery Technologies for Protein and Peptide Therapeutics." Current Pharmaceutical Biotechnology 7, no. 4 (August 1, 2006): 261–76. http://dx.doi.org/10.2174/138920106777950852.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Patel, RR, and JK Patel. "Novel technologies of oral controlled release drug delivery system." Systematic Reviews in Pharmacy 1, no. 2 (2010): 128. http://dx.doi.org/10.4103/0975-8453.75054.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Temsamani, Jamal, Jean-Michel Scherrmann, Anthony R. Rees, and Michel Kaczorek. "Brain drug delivery technologies: novel approaches for transporting therapeutics." Pharmaceutical Science & Technology Today 3, no. 5 (May 2000): 155–62. http://dx.doi.org/10.1016/s1461-5347(00)00258-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Panzner, Steffen, and Philip L. Smith. "9th International drug delivery technologies & deal-making summit." Expert Opinion on Drug Delivery 2, no. 1 (January 2005): 189–90. http://dx.doi.org/10.1517/17425247.2.1.189.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Bhavsar, Mayank D., and Mansoor M. Amiji. "Polymeric nano- and microparticle technologies for oral gene delivery." Expert Opinion on Drug Delivery 4, no. 3 (May 2007): 197–213. http://dx.doi.org/10.1517/17425247.4.3.197.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Plaunt, Adam J., Tam L. Nguyen, Michel R. Corboz, Vladimir S. Malinin, and David C. Cipolla. "Strategies to Overcome Biological Barriers Associated with Pulmonary Drug Delivery." Pharmaceutics 14, no. 2 (January 27, 2022): 302. http://dx.doi.org/10.3390/pharmaceutics14020302.

Full text

Abstract:

While the inhalation route has been used for millennia for pharmacologic effect, the biological barriers to treating lung disease created real challenges for the pharmaceutical industry until sophisticated device and formulation technologies emerged over the past fifty years. There are now several inhaled device technologies that enable delivery of therapeutics at high efficiency to the lung and avoid excessive deposition in the oropharyngeal region. Chemistry and formulation technologies have also emerged to prolong retention of drug at the active site by overcoming degradation and clearance mechanisms, or by reducing the rate of systemic absorption. These technologies have also been utilized to improve tolerability or to facilitate uptake within cells when there are intracellular targets. This paper describes the biological barriers and provides recent examples utilizing formulation technologies or drug chemistry modifications to overcome those barriers.

APA, Harvard, Vancouver, ISO, and other styles

34

Gazzaniga, Andrea, Saliha Moutaharrik, Ilaria Filippin, Anastasia Foppoli, Luca Palugan, Alessandra Maroni, and Matteo Cerea. "Time-Based Formulation Strategies for Colon Drug Delivery." Pharmaceutics 14, no. 12 (December 9, 2022): 2762. http://dx.doi.org/10.3390/pharmaceutics14122762.

Full text

Abstract:

Despite poor absorption properties, delivery to the colon of bioactive compounds administered by the oral route has become a focus of pharmaceutical research over the last few decades. In particular, the high prevalence of Inflammatory Bowel Disease has driven interest because of the need for improved pharmacological treatments, which may provide high local drug concentrations and low systemic exposure. Colonic release has also been explored to deliver orally biologics having gut stability and permeability issues. For colon delivery, various technologies have been proposed, among which time-dependent systems rely on relatively constant small intestine transit time. Drug delivery platforms exploiting this physiological feature provide a lag time programmed to cover the entire small intestine transit and control the onset of release. Functional polymer coatings or capsule plugs are mainly used for this purpose, working through different mechanisms, such as swelling, dissolution/erosion, rupturing and/or increasing permeability, all activated by aqueous fluids. In addition, enteric coating is generally required to protect time-controlled formulations during their stay in the stomach and rule out the influence of variable gastric emptying. In this review, the rationale and main delivery technologies for oral colon delivery based on the time-dependent strategy are presented and discussed.

APA, Harvard, Vancouver, ISO, and other styles

35

Bansal, Monisha, and Shahid Jamil. "MICELLAR MICROPARTICLES: A NOVEL APPROACH TO TOPICAL DRUG DELIVERY SYSTEM." International Journal of Applied Pharmaceutics 10, no. 5 (September 8, 2018): 1. http://dx.doi.org/10.22159/ijap.2018v10i5.27506.

Full text

Abstract:

Topical drug delivery system is defined as the pharmaceutical dosage form which when applied onto the skin provides protection of skin and prevents serious skin disorders. Topical drug are being used for several years and still have its potential in new pharmaceutical technologies investigated. Skin is the most easily accessible organ of the body which has the potential to facilitate the delivery of several drugs with better efficacy, confining the pharmacological or other effect of the drug to the surface of the skin. Micelles are colloidal particles with a size smaller than 100 nm that allow a great depth of tissue penetration for targeted drug delivery, but rapidly disintegrate in the body. Microparticles containing micelles have the potential for delivering hydrophobic drug encapsulated in micelles on the target site in the specific part of the body. Micellar microparticles allow the improvement of solubility and dissolution of poorly soluble drugs. Microparticles containing micelles have the potential for delivering micelle-encapsulated hydrophobic drugs in targeted therapy. This article reviews the topical drug delivery system, colloidal drug delivery system and aspects and literature reviewed on micellar microparticles and its advantages in pharmaceuticals. An overview of reviews was conducted to locate published literature between 2000 and 2017.

APA, Harvard, Vancouver, ISO, and other styles

36

Noah, Lars. "Challenges in the Federal Regulation of Pain Management Technologies." Journal of Law, Medicine & Ethics 31, no. 1 (2003): 55–74. http://dx.doi.org/10.1111/j.1748-720x.2003.tb00059.x.

Full text

Abstract:

Those who write about pain management have focused almost entirely on delivery issues, paying essentially no attention to the federal regulatory challenges that affect the development of pain relief technologies — namely, pharmaceuticals and medical devices indicated for analgesic uses. The academic literature is strangely devoid of any sophisticated discussion of the difficulties that attend, first, the product approval decisions of the Food and Drug Administration (FDA) and, second, the scheduling decisions made by the Drug Enforcement Administration (DEA). If a “bottleneck” develops upstream, it could have serious repercussions downstream — without pain relief technologies, the issues of access that have preoccupied previous commentators would have little practical consequence.The modern pharmaceutical industry traces its origins back more than a century, around the time that the German company Bayer first synthesized aspirin (acetylsalicylic acid) and began marketing it as an analgesic.

APA, Harvard, Vancouver, ISO, and other styles

37

Nanjwade, B. K., S. A. Adichwal, K. R. Gaikwad, K. A. Parikh, and F. V. Manvi. "Pulmonary Drug Delivery: Novel Pharmaceutical Technologies Breathe New Life into the Lungs." PDA Journal of Pharmaceutical Science and Technology 65, no. 5 (September 1, 2011): 513–34. http://dx.doi.org/10.5731/pdajpst.2011.00704.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

LIU, FANG, WEI HE, CHUNLI CAO, and YI LIU. "CFD SIMULATION AND CHARACTERIZATION OF A DEVICE FOR POWDERED PHARMACEUTICALS AND BIOLOGICALS DELIVERY." Journal of Mechanics in Medicine and Biology 06, no. 03 (September 2006): 285–97. http://dx.doi.org/10.1142/s0219519406001923.

Full text

Abstract:

Advances in molecular biology have produced a wide range of protein and peptide-based drugs. Equally, it is required to explore various technologies and capabilities to deliver those drugs. A unique medical device, the hand-held biolistics, is developed for powdered pharmaceuticals/biologicals transdermal delivery. The underlying principle is to accelerate micro-particles by means of a high-speed helium gas to an appropriate momentum to penetrate the outer layer of the skin to elicit desirable pharmaceutical/biological effects. The novelty of this hand-held biolistics is using the venturi effect to entrain micron-sized protein and peptide drugs into an established quasi-steady transonic jet flow and accelerate them toward the target. In this paper, computational fluid dynamics is utilized to characterize prototype biolistic system. The key features of gas dynamics and gas–particle interaction are presented. The overall capability of the biolistic delivery system is discussed and demonstrated. The statistical analyses show that the particles have achieved a mean velocity of 628 m/s as representatives of extracellular vaccine delivery applications.

APA, Harvard, Vancouver, ISO, and other styles

39

Maeki, Masatoshi, Shuya Uno, Ayuka Niwa, Yuto Okada, and Manabu Tokeshi. "Microfluidic technologies and devices for lipid nanoparticle-based RNA delivery." Journal of Controlled Release 344 (April 2022): 80–96. http://dx.doi.org/10.1016/j.jconrel.2022.02.017.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Gala, Rikhav P., Javier O. Morales, and Jason T. McConville. "Preface to advances in thin film technologies in drug delivery." International Journal of Pharmaceutics 571 (November 2019): 118687. http://dx.doi.org/10.1016/j.ijpharm.2019.118687.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Quaglia, Fabiana. "Bioinspired tissue engineering: The great promise of protein delivery technologies." International Journal of Pharmaceutics 364, no. 2 (December 2008): 281–97. http://dx.doi.org/10.1016/j.ijpharm.2008.04.030.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Brambilla, Davide, Paola Luciani, and Jean-Christophe Leroux. "Breakthrough discoveries in drug delivery technologies: The next 30 years." Journal of Controlled Release 190 (September 2014): 9–14. http://dx.doi.org/10.1016/j.jconrel.2014.03.056.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Magdanz, Veronika, and Oliver G. Schmidt. "Spermbots: potential impact for drug delivery and assisted reproductive technologies." Expert Opinion on Drug Delivery 11, no. 8 (May 31, 2014): 1125–29. http://dx.doi.org/10.1517/17425247.2014.924502.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

Shah, J. M., N. H. Shah, and Hadiya P D. "Recent Advances in Novasome Formulation Technology." International Journal of Pharmaceutical Sciences and Nanotechnology 7, no. 2 (May 31, 2014): 2407–11. http://dx.doi.org/10.37285/ijpsn.2014.7.2.1.

Full text

Abstract:

Pharmaceutical technology has developed various newer modes of novel drug delivery aspects. Modifications in the previously existing drug delivery methods have led to various newly innovated technologies serving as a safe and effective means of improvement over the existing ones. Novasome technology is one of the new innovations of liposomes which have solved many of the problems related to liposomal drug delivery system. It offers a seven bilayer membrane which has the ability to incorporate both water soluble and insoluble drugs. It has an excellent entrapment efficiency which provides better medication. Formulation of novasomes is achieved in a high shear device. Due to its numerous advantages, novasomes have been used extensively in various fields like cosmetics, chemical, personal care, foods, pharmaceuticals and agrochemicals.

APA, Harvard, Vancouver, ISO, and other styles

45

Lim, Michael, Abu Zayed Md Badruddoza, Jannatul Firdous, Mohammad Azad, Adnan Mannan, Taslim Ahmed Al-Hilal, Chong-Su Cho, and Mohammad Ariful Islam. "Engineered Nanodelivery Systems to Improve DNA Vaccine Technologies." Pharmaceutics 12, no. 1 (January 1, 2020): 30. http://dx.doi.org/10.3390/pharmaceutics12010030.

Full text

Abstract:

DNA vaccines offer a flexible and versatile platform to treat innumerable diseases due to the ease of manipulating vaccine targets simply by altering the gene sequences encoded in the plasmid DNA delivered. The DNA vaccines elicit potent humoral and cell-mediated responses and provide a promising method for treating rapidly mutating and evasive diseases such as cancer and human immunodeficiency viruses. Although this vaccine technology has been available for decades, there is no DNA vaccine that has been used in bed-side application to date. The main challenge that hinders the progress of DNA vaccines and limits their clinical application is the delivery hurdles to targeted immune cells, which obstructs the stimulation of robust antigen-specific immune responses in humans. In this updated review, we discuss various nanodelivery systems that improve DNA vaccine technologies to enhance the immunological response against target diseases. We also provide possible perspectives on how we can bring this exciting vaccine technology to bedside applications.

APA, Harvard, Vancouver, ISO, and other styles

46

Basit, Abdul. "Recent innovations in 3D-printed personalized medicines: an interview with Abdul Basit." Journal of 3D Printing in Medicine 4, no. 1 (March 2020): 5–7. http://dx.doi.org/10.2217/3dp-2020-0010.

Full text

Abstract:

Abdul Basit holds the position of Professor of Pharmaceutics at the UCL School of Pharmacy, University College London (UK). Basit is an internationally leading authority on oral drug delivery, digital health and innovative pharmaceutical technologies including 3D printing. Basit is a world authority on translational research; he has founded two spin-out companies (FabRx Ltd and Intract Pharma, both in London, UK) and has invented several drug products that have entered the clinic. More than a million patients to date have benefited from the treatments originating from his laboratory. Across his career, Basit has received prestigious awards from the American Association of Pharmaceutical Scientists, Academy of Pharmaceutical Sciences, GlaxoSmithKline and AstraZeneca and was listed among the world’s most highly influential researchers in 2019.

APA, Harvard, Vancouver, ISO, and other styles

47

Alkilani, Ahlam Zaid, Jehad Nasereddin, Rania Hamed, Sukaina Nimrawi, Ghaid Hussein, Hadeel Abo-Zour, and Ryan F. Donnelly. "Beneath the Skin: A Review of Current Trends and Future Prospects of Transdermal Drug Delivery Systems." Pharmaceutics 14, no. 6 (May 28, 2022): 1152. http://dx.doi.org/10.3390/pharmaceutics14061152.

Full text

Abstract:

The ideal drug delivery system has a bioavailability comparable to parenteral dosage forms but is as convenient and easy to use for the patient as oral solid dosage forms. In recent years, there has been increased interest in transdermal drug delivery (TDD) as a non-invasive delivery approach that is generally regarded as being easy to administer to more vulnerable age groups, such as paediatric and geriatric patients, while avoiding certain bioavailability concerns that arise from oral drug delivery due to poor absorbability and metabolism concerns. However, despite its many merits, TDD remains restricted to a select few drugs. The physiology of the skin poses a barrier against the feasible delivery of many drugs, limiting its applicability to only those drugs that possess physicochemical properties allowing them to be successfully delivered transdermally. Several techniques have been developed to enhance the transdermal permeability of drugs. Both chemical (e.g., thermal and mechanical) and passive (vesicle, nanoparticle, nanoemulsion, solid dispersion, and nanocrystal) techniques have been investigated to enhance the permeability of drug substances across the skin. Furthermore, hybrid approaches combining chemical penetration enhancement technologies with physical technologies are being intensively researched to improve the skin permeation of drug substances. This review aims to summarize recent trends in TDD approaches and discuss the merits and drawbacks of the various chemical, physical, and hybrid approaches currently being investigated for improving drug permeability across the skin.

APA, Harvard, Vancouver, ISO, and other styles

48

Auriemma, Giulia, Paola Russo, Pasquale Del Gaudio, Carlos A. García-González, Mariana Landín, and Rita Patrizia Aquino. "Technologies and Formulation Design of Polysaccharide-Based Hydrogels for Drug Delivery." Molecules 25, no. 14 (July 10, 2020): 3156. http://dx.doi.org/10.3390/molecules25143156.

Full text

Abstract:

Polysaccharide-based hydrogel particles (PbHPs) are very promising carriers aiming to control and target the release of drugs with different physico-chemical properties. Such delivery systems can offer benefits through the proper encapsulation of many drugs (non-steroidal and steroidal anti-inflammatory drugs, antibiotics, etc) ensuring their proper release and targeting. This review discusses the different phases involved in the production of PbHPs in pharmaceutical technology, such as droplet formation (SOL phase), sol-gel transition of the droplets (GEL phase) and drying, as well as the different methods available for droplet production with a special focus on prilling technique. In addition, an overview of the various droplet gelation methods with particular emphasis on ionic cross-linking of several polysaccharides enabling the formation of particles with inner highly porous network or nanofibrillar structure is given. Moreover, a detailed survey of the different inner texture, in xerogels, cryogels or aerogels, each with specific arrangement and properties, which can be obtained with different drying methods, is presented. Various case studies are reported to highlight the most appropriate application of such systems in pharmaceutical field. We also describe the challenges to be faced for the breakthrough towards clinic studies and, finally, the market, focusing on the useful approach of safety-by-design (SbD).

APA, Harvard, Vancouver, ISO, and other styles

49

Aguilar-de-Leyva, Ángela, Vicente Linares, Marta Casas, and Isidoro Caraballo. "3D Printed Drug Delivery Systems Based on Natural Products." Pharmaceutics 12, no. 7 (July 3, 2020): 620. http://dx.doi.org/10.3390/pharmaceutics12070620.

Full text

Abstract:

In the last few years, the employment of 3D printing technologies in the manufacture of drug delivery systems has increased, due to the advantages that they offer for personalized medicine. Thus, the possibility of producing sophisticated and tailor-made structures loaded with drugs intended for tissue engineering and optimizing the drug dose is particularly interesting in the case of pediatric and geriatric population. Natural products provide a wide range of advantages for their application as pharmaceutical excipients, as well as in scaffolds purposed for tissue engineering prepared by 3D printing technologies. The ability of biopolymers to form hydrogels is exploited in pressure assisted microsyringe and inkjet techniques, resulting in suitable porous matrices for the printing of living cells, as well as thermolabile drugs. In this review, we analyze the 3D printing technologies employed for the preparation of drug delivery systems based on natural products. Moreover, the 3D printed drug delivery systems containing natural products are described, highlighting the advantages offered by these types of excipients.

APA, Harvard, Vancouver, ISO, and other styles

50

Bhalani, Dixit, Bhingaradiya Nutan, Avinash Kumar, and Arvind Singh Chandel. "Bioavailability Enhancement Techniques for Poorly Aqueous Soluble Drugs and Therapeutics." Biomedicines 10, no. 9 (August 23, 2022): 2055. http://dx.doi.org/10.3390/biomedicines10092055.

Full text

Abstract:

The low water solubility of pharmacoactive molecules limits their pharmacological potential, but the solubility parameter cannot compromise, and so different approaches are employed to enhance their bioavailability. Pharmaceutically active molecules with low solubility convey a higher risk of failure for drug innovation and development. Pharmacokinetics, pharmacodynamics, and several other parameters, such as drug distribution, protein binding and absorption, are majorly affected by their solubility. Among all pharmaceutical dosage forms, oral dosage forms cover more than 50%, and the drug molecule should be water-soluble. For good therapeutic activity by the drug molecule on the target site, solubility and bioavailability are crucial factors. The pharmaceutical industry’s screening programs identified that around 40% of new chemical entities (NCEs) face various difficulties at the formulation and development stages. These pharmaceuticals demonstrate less solubility and bioavailability. Enhancement of the bioavailability and solubility of drugs is a significant challenge in the area of pharmaceutical formulations. According to the Classification of Biopharmaceutics, Class II and IV drugs (APIs) exhibit poor solubility, lower bioavailability, and less dissolution. Various technologies are discussed in this article to improve the solubility of poorly water-soluble drugs, for example, the complexation of active molecules, the utilization of emulsion formation, micelles, microemulsions, cosolvents, polymeric micelle preparation, particle size reduction technologies, pharmaceutical salts, prodrugs, the solid-state alternation technique, soft gel technology, drug nanocrystals, solid dispersion methods, crystal engineering techniques and nanomorph technology. This review mainly describes several other advanced methodologies for solubility and bioavailability enhancement, such as crystal engineering, micronization, solid dispersions, nano sizing, the use of cyclodextrins, solid lipid nanoparticles, colloidal drug delivery systems and drug conjugates, referring to a number of appropriate research reports.

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!